Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2618 + penpulimab + anlotinib
- Development stage
- Phase 1
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy comprising **TQB2618** (a TIM-3 blocking monoclonal antibody), **penpulimab** (an anti-PD-1 monoclonal antibody), and **anlotinib** (a small molecule multi-targeted tyrosine kinase inhibitor) under clinical investigation for the treatment of advanced or metastatic nasopharyngeal carcinoma. TQB2618 is designed to block T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), thereby potentially enhancing immune response against tumors. Penpulimab blocks the PD-1 checkpoint, enhancing immune-mediated tumor cell killing, while anlotinib targets several receptor tyrosine kinases including VEGFR, FGFR, PDGFR, and c-Kit, inhibiting tumor angiogenesis and proliferation[4][6].
- Other names
- TQB2618 + penpulimab + anlotinibTQB2618 injection combined with penpulimab injection and anlotinib hydrochloride capsulesTQB-2618 injection combined with penpulimab injection and anlotinib hydrochloride capsulesTQB 2618 injection combined with penpulimab injection and anlotinib hydrochloride capsules
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on TQB2618 + penpulimab + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2618 + penpulimab + anlotinib.